However, the relationship between dihydropyrimidine dehydrogenase (DPD), a 5-FU degrading enzyme, and EGFR mutation status is unknown.
Lièvre A, Bachet J, Le Corre D, Boige V, Landi B, Emile J et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
Epidermal growth factor receptor (EGFR) exon 19 mutation status is a very important prediction index for tyrosine kinase inhibitors (TKIs) therapy.
The clinical utility of ARID1A mutation status is currently unclear, due to a limited number of sufficiently powered studies.
Furthermore, TET2 mutation status is significantly correlated with decreased global 5-hmC in myeloid tumors (Ko et al., 2010; Konstandin et al., 2011).
PIK3CA mutation status did not appear to predict better or worse response to IFL therapy compared with FU/LV therapy (P interaction) >.16 .Overall tumor PIK3CA mutation status is not associated with stage III colon cancer prognosis.
To guide and optimize treatment decisions, especially for NSCLC patients in stage III and IV, EGFR and KRAS mutation status is often required.
The GNAQ mutation status is not suitable to predict DFS.
Mutation status is traditionally assessed by analysis of DNA extracted from archival tumour tissue samples.
The IGHV gene mutation status is one of the most reliable prognostic markers.
p53 mutation status is most commonly characterized by direct DNA sequencing or by immunohistochemistry (IHC).
